methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxo-pyrimidin-1-yl]-3-hydroxy-oxolan-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate

Names

[ Name ]:
methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxo-pyrimidin-1-yl]-3-hydroxy-oxolan-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate

[Synonym ]:
5-(2-Bromovinyl)-2'-deoxy-5'-uridyl-phenyl-alanylphosphoramidate,trans
Thymectacin
UNII-2ZRZ4TSW3F
E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(L-methylalaninyl)-phenylphosphoramidate
BVDU prodrug
Brivudine phosphoramidate
(E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl phenyl L-methoxyalaninylphosphoramidate
L-Alanine,N-(5-((1E)-2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl)-,methyl ester
NB1011

Biological Activity

[Description]:

Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS). Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin)[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vitro]

Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS)[1].

[References]

[1]. Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist. 2006;11(9):1018-1024.

[2]. Congiatu C, et al. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. J Med Chem. 2006;49(2):452-455.

Chemical & Physical Properties

[ Density]:
1.597g/cm3

[ Molecular Formula ]:
C₂₁H₂₅BrN₃O₉P

[ Molecular Weight ]:
574.31600

[ Exact Mass ]:
573.05100

[ PSA ]:
168.25000

[ LogP ]:
2.70860

[ Index of Refraction ]:
1.625